Allurion Technologies (ALUR) AI Stock Analysis

• Market Cap: $12.97M
• Dividend Yield: N/A
• Average Volume (3M): 352.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.71
• Revenue Growth: -50.49%
• EPS Growth: 39.93%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -1.53
• Shares Outstanding: 9,262,586
• 10 Day Avg. Volume: 49,347
• 30 Day Avg. Volume: 352,549
• PEG Ratio: 0.01
• Price to Book (P/B): -0.31
• Price to Sales (P/S): 0.75
• P/FCF Ratio: -0.56
• Enterprise Value/Market Cap: 3.33
• Enterprise Value/Revenue: 2.51
• Enterprise Value/Gross Profit: 4.11
• Enterprise Value/Ebitda: -1.29
• 1Y Price Target: $6.00
• Price Target Upside: 376.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -4.2
• Revenue Forecast (FY): $14.54M

• Rating: 44 Neutral
• Price Target: $1.50 ▲(19.05% Upside)

Allurion Technologies' overall stock score is primarily impacted by its poor financial performance, characterized by persistent losses and high leverage. While recent corporate events and strategic initiatives show promise, the stock's technical indicators and valuation remain weak, reflecting ongoing challenges in achieving profitability and market confidence.

Positive Factors

FDA Approval Progress

Achieving FDA approval milestones enhances Allurion's market potential in the U.S., supporting long-term growth by expanding its product reach.

Debt Restructuring

Converting debt to equity reduces financial leverage, improving balance sheet health and providing greater financial flexibility for future operations.

R&D Innovations

Innovative R&D efforts, like the drug-eluting balloon, position Allurion to lead in obesity therapy, potentially enhancing competitive advantage and market share.

Negative Factors

Revenue Decline

Significant revenue decline indicates challenges in maintaining sales momentum, which could impact long-term financial stability and growth prospects.

Negative Cash Flows

Negative cash flows highlight liquidity challenges, potentially limiting Allurion's ability to invest in growth initiatives and sustain operations without external funding.

High Leverage

High leverage poses risks to financial stability, increasing vulnerability to economic downturns and limiting strategic financial options.

Allurion Technologies Business Overview & Revenue Model

Company Description

Allurion Technologies (ALUR) is a medical technology company focused on developing innovative solutions for weight management and obesity treatment. The company operates primarily in the healthcare sector, offering a range of products aimed at helping individuals achieve sustainable weight loss. Its core product, the Allurion Balloon, is an intragastric balloon that aids in weight loss by promoting a feeling of fullness, and is part of a comprehensive program that includes lifestyle coaching and nutritional support.

How the Company Makes Money

Allurion Technologies generates revenue through the sale of its medical devices, particularly the Allurion Balloon and associated services. The company typically sells its products directly to healthcare providers, hospitals, and clinics, which then offer these solutions to patients seeking weight loss options. Additionally, Allurion has developed partnerships with healthcare institutions and professionals to enhance the distribution of its products and services, creating a network that expands its market reach. The company may also generate income through subscription services for ongoing support and coaching, contributing to a recurring revenue model. Furthermore, Allurion's collaborations with insurance companies can facilitate reimbursement for its products, enhancing access to patients and driving sales.

Allurion Technologies Financial Statement Overview

Summary

Allurion Technologies faces significant financial challenges, including declining revenue, persistent losses, high leverage, and negative cash flows. Strategic changes are necessary to stabilize and improve financial health in a highly competitive medical devices industry.

Income Statement

Allurion Technologies has experienced significant revenue fluctuations, with a notable decline from 2022 to 2023. The company faces negative profit margins, including a negative gross profit margin in 2024, and sustained losses in net income, EBIT, and EBITDA, indicating ongoing challenges in achieving profitability.

Balance Sheet

The balance sheet reveals a concerning financial structure, with negative stockholders' equity and high leverage as indicated by a high debt-to-equity ratio. The equity ratio is negative, reflecting a risk of insolvency, compounded by the decline in assets and insufficient equity to cover liabilities.

Cash Flow

Cash flow analysis shows persistently negative operating and free cash flows, signaling liquidity issues. The company has relied heavily on financing activities to fund operations, which is unsustainable in the long term without improved financial performance.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.21M	32.11M	53.47M	64.21M	38.24M	0.00
Gross Profit	10.49M	21.50M	41.50M	50.73M	29.19M	0.00
EBITDA	-33.37M	-22.17M	-69.03M	-32.28M	-8.01M	201.13K
Net Income	-43.29M	-26.15M	-80.61M	-37.74M	-12.39M	-5.17K
Balance Sheet
Total Assets	18.14M	32.81M	71.71M	51.37M	39.35M	329.96K
Cash, Cash Equivalents and Short-Term Investments	6.14M	15.38M	38.04M	7.68M	25.84M	47.09K
Total Debt	33.39M	37.92M	41.86M	59.53M	26.14M	170.00K
Total Liabilities	101.07M	110.79M	142.20M	83.68M	73.64M	310.13K
Stockholders Equity	-82.93M	-77.98M	-70.49M	-32.31M	-34.28M	19.83K
Cash Flow
Free Cash Flow	-36.90M	-42.91M	-65.59M	-48.53M	-15.24M	-40.00
Operating Cash Flow	-36.90M	-42.30M	-63.98M	-46.98M	-14.33M	―
Investing Cash Flow	0.00	-611.00K	-1.61M	-1.55M	-912.00K	0.00
Financing Cash Flow	14.32M	20.21M	95.99M	30.54M	28.95M	47.13K

Allurion Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALUR, the sentiment is Negative. The current price of 1.26 is below the 20-day moving average (MA) of 1.56, below the 50-day MA of 1.65, and below the 200-day MA of 2.31, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 39.12 is Neutral, neither overbought nor oversold. The STOCH value of 25.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALUR.

Allurion Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVNO	58 Neutral	$6.57M	-0.30	-57.19%	―	―	18.94%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IRIX	46 Neutral	$17.71M	-3.64	-139.29%	―	4.58%	55.26%
ALUR	44 Neutral	$12.97M	-0.19	―	―	-50.49%	39.93%
XAIR	44 Neutral	$7.38M	-0.11	-179.63%	―	147.74%	73.23%
CODX	42 Neutral	$15.66M	-0.26	-62.12%	―	-87.84%	29.16%
SINT	40 Underperform	$13.83M	-0.53	-204.04%	―	-60.89%	94.49%

Allurion Technologies Corporate Events

Allurion Shareholders Approve Governance Changes and Capital Actions

At its annual meeting on December 18, 2025, Allurion Technologies, Inc. re-elected directors Omar Ishrak, Douglas Hudson and R. Jason Richey to serve until the 2028 annual meeting and ratified Deloitte & Touche LLP as its independent auditor for the 2025 fiscal year. Shareholders also approved an amended and restated 2023 Stock Option and Incentive Plan that increases the share pool, extends the plan term, revises the fully diluted share definition and lowers non-employee director compensation limits, as well as the repricing of certain existing stock options. In addition, investors authorized the issuance of common shares upon conversion of Series B preferred stock and the exercise of private placement warrants to ensure compliance with New York Stock Exchange listing rules, and backed a share consolidation authorization allowing the board to implement a reverse stock split in a range of 1-for-1.5 to 1-for-20, steps that collectively enhance the company’s capital structure flexibility and support its continued listing and governance framework.

Allurion Technologies Secures $5M in New Funding

On November 11, 2025, Allurion Technologies entered into a securities purchase agreement to sell shares and warrants for approximately $5 million, aiming to strengthen its balance sheet. Concurrently, the company agreed to exchange outstanding debt for convertible preferred equity with RTW Investments, which will allow RTW to convert debt into Series B Preferred Stock, enhancing Allurion’s financial position. These strategic financial maneuvers are part of Allurion’s broader efforts to secure FDA approval for its products and position itself for long-term success in the weight-loss industry.